(Q38137764)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Predictive biomarkers for cancer therapy with PARP inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Murat Saparbaev

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Maria Castedo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

5

G Kroemer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

J Michels

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

16 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

3894-3907

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2013.352

21 February 2020

exact match

0 references

cites work

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A family of macrodomain proteins reverses cellular mono-ADP-ribosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Involvement of poly(ADP-ribose) polymerase in base excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP is important for genomic stability but dispensable in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP regulates nonhomologous end joining through retention of Ku at double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Visualization of a DNA-PK/PARP1 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP-3 and APLF function together to accelerate nonhomologous end-joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Alkylating DNA damage stimulates a regulated form of necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP-1 is involved in autophagy induced by DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

ROS-induced DNA damage and PARP-1 are required for optimal induction of starvation-induced autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

To die or to live: the dual role of poly(ADP-ribose) polymerase-1 in autophagy and necrosis under oxidative stress and DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Cisplatin resistance associated with PARP hyperactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Beyond DNA repair, the immunological role of PARP-1 and its siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Repairing DNA-methylation damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Cellular roles of dna topoisomerases: a molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Targeting XRCC1 deficiency in breast cancer for personalized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mantle cell lymphoma is characterized by inactivation of the ATM gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Regulation of Rad51 function by c-Abl in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Resistance to PARP-Inhibitors in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Brca1 controls homology-directed DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

PARI overexpression promotes genomic instability and pancreatic tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Enzymology of the repair of free radicals-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Excision of hypoxanthine from DNA containing dIMP residues by the Escherichia coli, yeast, rat, and human alkylpurine DNA glycosylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Enzymology of repair of etheno-adducts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Targeted deletion of mNth1 reveals a novel DNA repair enzyme activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Nucleotide excision repair and its connection with cancer and ageing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The DNA-damage response in human biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Defective homologous recombination in human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mutator pathways unleashed by epigenetic silencing in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

21 January 2018

PARP goes transcription

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

(ADP-ribose)n participates in DNA excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

AMPK mediates a pro-survival autophagy downstream of PARP-1 activation in response to DNA alkylating agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

The ETS-domain transcription factor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.352

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

1016764759

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037533%20AND%20SRC:MED&resulttype=core&format=json